Request Trial
istock-694728278_durktalsma
DurkTalsma / iStockphoto.com
1 June 2018AmericasJennifer Fox

Post-grant proceedings: shaping the biotech landscape

In March 2010, the Biologics Price Competition and Innovation Act (BPCIA) created an abbreviated pathway for licensing biosimilars and a 12-year exclusivity period for first licensed biologics. Shortly after, the America Invents Act (AIA) provided multiple changes to the patent system and established a variety of post-grant proceedings. Notably, the AIA established post-grant review (PGR) proceedings and inter partes review (IPR) proceedings.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Abbott IP chief: ‘Firms without AI policies scare me’
5 March 2026   The healthcare company’s chief IP counsel is researching how law firms and patent attorneys are using AI tools to inform its own guidelines for external legal providers.
Americas
Moderna inks billion-dollar deal to settle long-running Spikevax dispute
5 March 2026   Moderna settles, agreeing to part with up to $2.25 billion to avoid a trial and secure a licence to continue using the platform underpinning its COVID-19 vaccine.
Americas
To cite or not to cite: How can we avoid misuse of AI in court?
4 March 2026   With an increase in ‘hallucinated’ case law cited as evidence in courts globally, what can legal practitioners—as well as providers of AI tools and platforms—do to help safeguard against this? Sarah Speight finds out.


Editor's picks

Abbott IP chief: ‘Firms without AI policies scare me’
Americas
Abbott IP chief: ‘Firms without AI policies scare me’
5 March 2026

Editor's picks

Americas
Abbott IP chief: ‘Firms without AI policies scare me’
5 March 2026
Americas
SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
26 February 2026
Americas
Eli Lilly escapes $278m payout in biotech licensing dispute
26 February 2026
Americas
Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’
10 February 2026
Asia
AstraZeneca partners with Chinese firm ahead of next obesity race
5 February 2026
Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026

More features

Nomination call: Influential Women in IP list closes ahead of International Women’s Day
Abbott IP chief: ‘Firms without AI policies scare me’
Moderna inks billion-dollar deal to settle long-running Spikevax dispute
DWT recruits first-chair trial litigator as latest hire in IP expansion
FisherBroyles opens San Diego office
To cite or not to cite: How can we avoid misuse of AI in court?
Emotional Perception: What next for patent holders?
LSPN Awards 2026 finalists revealed